Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin

NCT03211156 | Completed Phase 2 Results

• 1 other identifier: 16-0073
• Study Type: interventional
• Target: 97
• Locations: 1 country
• Sites: 2

Brief Summary

This is a randomized, double-blind, placebo-controlled Phase 2 study designed to determine if amoxicillin will eradicate vaginal colonization/infection with Gardnerella vaginalis (GV) when administered to women who are colonized/infected with GV but have no clinical evidence of Bacterial Vaginosis (BV). The study will be conducted at 2 clinics in the United States: University of Alabama at Birmingham and Wake Forest University Health Sciences. Entire study duration is approximately 24 months and subject participation duration is approximately 22 days. Approximately 245 healthy adult females, 18 to 45 years of age will be screened to enroll approximately 98 participants to achieve 82 evaluable participants at the test of cure (ToC) visit. Participants will be enrolled and randomized to one of two groups, either amoxicillin (2 x 250 mg capsules by mouth twice daily for 7 days) or placebo. Women who are enrolled will be asked to return for one further visit, Visit 2 (Day 15 - 21), where a ToC will be completed. For those not enrolled, participation will end at their post screening follow up phone call. Women will be asked to use condoms during their participation. The primary objective is to determine if treatment with amoxicillin eradicates GV in women who are colonized/infected with GV but have no clinical evidence of BV.

Conditions

Vaginitis Gardnerella

Keywords

Amoxicillin; Gardnerella vaginalis; Vaginal Colonization

Outcome Measures

Primary Outcomes (1)

• The Proportion of Participants With Eradication of Gardnerella Vaginalis (GV) in Each Study Arm at Visit 2 (Day 15-21) as Assessed by Nucleic Acid Amplification Test (NAAT).

  Eradication of GV is defined by a negative NAAT result for GV at Visit 2. Participants who have a missing GV NAAT result at the test of cure (TOC) visit were classified as treatment failures. The denominator for proportions is based on the number of subjects who were randomized to the specified treatment group.

  Day 15 to 21

Secondary Outcomes (1)

• The Proportion of Participants Reporting Related Adverse Events (AEs and SAEs) in Each Study Arm Following the First Dose of Study Product Through Visit 2.

  Day 1 through Day 15 to 21

Study Arms (2)

Placebo arm

PLACEBO COMPARATOR

Placebo 2 capsules PO twice a day for 7 days, n=49

Other: Placebo

Treatment arm

EXPERIMENTAL

Amoxicillin 2 x 250 mg capsules PO twice a day for 7 days, n=49

Drug: Amoxicillin

Interventions

Amoxicillin DRUG

Amoxicillin is an aminopenicillin antibiotic

Treatment arm

Placebo OTHER

Placebo

Placebo arm

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Women ages 18-45, inclusive.
• No evidence of vaginitis (yeast, trichomonas, and BV/abnormal vaginal flora) or other vaginal conditions which in the opinion of the investigator could be confounders\*.
• \*These causes will initially be detected by wet mount microscopy with trichomonas during the screening procedures and later confirmed by NAAT and BV/abnormal vaginal flora confirmed by Nugent scoring (Nugent score of 4-10).
• Presence of GV detected by NAAT\*.
• \*Results of NAAT testing will be available prior to return for Enrollment visit.
• Willing to use condoms during vaginal intercourse while participating in the study.
• Not currently menstruating at screening visit.
• Willing and able to provide written informed consent.
• Negative urine pregnancy test on all participants of childbearing potential at study screening.
• Participant must be of non-childbearing potential\* or must be using highly effective birth control\*\* to avoid becoming pregnant.
• \*Non-childbearing potential is defined as being post-menopausal for at least 1 year, status after bilateral tubal ligation, or status after bilateral oophorectomy or status after hysterectomy.
• \*\*In addition to the required use of condoms by the male partner during study participation, participants must agree to avoid becoming pregnant by using one of the following acceptable method of birth control for 30 days prior to screening and for the duration of the study:
• Intrauterine contraceptive device; OR
• Oral contraceptives; OR
• Hormonal injections; OR

You may not qualify if:

• Pregnant or nursing.
• Allergic to penicillin, amoxicillin, cephalosporins, or other ß-lactam antibiotic.
• Use of antibiotics in the past 14 days prior to screening visit.
• HIV infected.
• Women taking immunosuppressive agents.
• \. History of renal impairment. 8. Use of any investigational drug within the past 30 days prior to screening. 9. Any other condition that, in the opinion of the investigator, would interfere with participation in the study.

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID): lead

Study Sites (2)

University of Alabama at Birmingham School of Medicine - Infectious Disease

Birmingham, Alabama, 35205, United States

Location

Guilford County Health Department - Greensboro - STD Clinic

Winston-Salem, North Carolina, 27157, United States

Location

MeSH Terms

Conditions

Vaginosis, Bacterial

Interventions

Amoxicillin

Condition Hierarchy (Ancestors)

Bacterial Infections; Bacterial Infections and Mycoses; Infections; Vaginitis; Vaginal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Intervention Hierarchy (Ancestors)

Ampicillin; Penicillin G; Penicillins; beta-Lactams; Lactams; Amides; Organic Chemicals; Sulfur Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Results Point of Contact

• Title: Jane Schwebke, MD
• Organization: University of Alabama at Birmingham

schwebke@uab.edu

205-975-5665

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: LTE60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 6, 2017
• First Posted: July 7, 2017
• Study Start: September 11, 2017
• Primary Completion: August 22, 2019
• Study Completion: August 22, 2019
• Last Updated: August 28, 2020
• Results First Posted: August 28, 2020

Record last verified: 2017-06-28

Locations

US (2)